Declaration of Interests
The authors declare that they have no known competing financial conflicts of interests or personal relationships that could have appeared to influence the work reported in this paper.
References
  1. Coronavirus Update (Live): 1,674,635 Cases and 96,734 Deaths from COVID-19 Virus Pandemic - Worldometer. Worldometers.info. https://www.worldometers.info/coronavirus/#countries. Published 2020. Accessed April 10, 2020.
  2. Ferguson N, Laydon D, Nedjati G et al. Non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. doi:10.25561/77482
  3. Lauren Krouse. Experts Say It’s Really Hard To Predict When The New Coronavirus Pandemic Will Be Over. Women’s Health. https://www.womenshealthmag.com/health/a31406983/when-will-coronavirus-end/. Published 2020. Accessed April 10, 2020.
  4. Bandara T, Musto R, Kancir J, Neudorf C. Public health physician perspectives on developing and deploying clinical practice guidelines during the 2009 H1N1 pandemic. Healthcare Management Forum . 2020:084047042091741. doi:10.1177/0840470420917412
  5. Yang Y, Peng F, Wang R et al. The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun . 2020;109:102434. doi:10.1016/j.jaut.2020.102434
  6. Karlsen A, Kruke B. The role of uncertainty during the ebola pandemic in western africa (2014–2016). Journal of Extreme Events . 2018;05(01):1850009. doi:10.1142/s2345737618500094
  7. Liu J, Zheng X, Tong Q et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol . 2020;92(5):491-494. doi:10.1002/jmv.25709
  8. Bielecka A, Mohammadi A. State-of-the-art in biosafety and biosecurity in European countries. Arch Immunol Ther Exp (Warsz) . 2014;62(3):169-178. doi:10.1007/s00005-014-0290-1
  9. Salerno R, Gaudioso J. Laboratory Biorisk Management: Biosafety And Biosecurity . CRC Press; 2015.
  10. Chosewood L, Wilson D. Biosafety In Microbiological And Biomedical Laboratories . [Washington D.C.]: U.S. Dept. of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institutes of Health; 2009.
  11. Zaki A. Biosafety and biosecurity measures: management of biosafety level 3 facilities. Int J Antimicrob Agents . 2010;36:S70-S74. doi:10.1016/j.ijantimicag.2010.06.026
  12. Baltz R, Davies J, Demain A. Manual Of Industrial Microbiology And Biotechnology . Washington, DC: ASM Press; 2010.
  13. World Health Organization. Laboratory Biosafety Manual, 3Rd Edition . World Health Organization; 2004.
  14. Peng H, Bilal M, Iqbal H. Improved biosafety and biosecurity measures and/or strategies to tackle laboratory-acquired infections and related risks. Int J Environ Res Public Health . 2018;15(12):2697. doi:10.3390/ijerph15122697
  15. Anderson R, Heesterbeek H, Klinkenberg D, Hollingsworth T. How will country-based mitigation measures influence the course of the COVID-19 epidemic?. The Lancet . 2020;395(10228):931-934. doi:10.1016/s0140-6736(20)30567-5
List of Figures
Figure 1. The distribution of Covid-19 in the first 20 nations with the highest cases.1
Figure 2. Daily new cases and daily death.1
List of Tables
Table 1. World Health Organization risk group classifications for microorganisms.13,14